Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types
B-cells quantity as a prediction for cancer patient survival
B-cells are a type of white blood cell that can help the body fight against foreign bodies, such as bacteria, virus, and even tumour cells. These immune cells can produce molecules called antibodies to identify any outsiders that enter the body, and activate immune responses to attack and destroy the invaders which are the potential pathogens.
Professor Vivian Wai Yan LUI, Associate Professor, School of Biomedical Sciences at CU Medicine, explained,“B-cells are like soldiers that guard the city gate. When an outsider appears at the gate, they check its identity and flag it to the General, the immune system in our bodies, in case of any danger. Then another type of immune cells, T-cells, work as weapons to attack and destroy the invader. The role of T-cells in cancer therapy has been well established in recent decades but the clinical impact of B-cells on cancer patient outcomes has been poorly defined till now.”
The bioinformatics research team led by Professor Vivian Lui, an expert in genomic medicine, has found, after studying cancer genomic and patient survival big data, that the level of B-cells in tumours is linked with the patient’s survival in seven major cancers (lower-grade glioma, diffuse large B-cell lymphoma, thymoma, kidney, lung, head and neck, and uterine cancers). The higher the level, the longer the survival. “This is a novel finding which provides insights into cancer prognosis”, said Professor Lui.
GPR18 gene identified as a novel genetic biomarker for cancer prognosis
Professor Lui’s team also performed a large-scale omics analysis on 29 cancer types and patient survival big data, and identified GPR18, a gene coding on the surface of a B-cell, which can help predict cancer patient survival in nine cancer types (melanoma, lower-grade glioma, sarcoma, cancers of the lung, head and neck, cervical, liver, breast, and adrenocortex).
In head and neck cancer alone, the team found that the higher the GPR18 level, the better the survival for a special subset of patient with human papillomavirus (HPV) infection.
| HPV-positive head and neck cancer patients | Overall survival period |
|---|---|
| with higher GPR18 expressions | 68.4 months |
| with lower GPR18 expressions | 57.4 months |
Professor Lui added, “GPR18 demonstrates versatile prognosticity in as many as nine cancer types, which is superior to other existing biomarkers such as CD20. Studies over the past decade failed to come into conclusion on the role of B-cells in human cancer prognosis in many cancer types. Our new findings help to conclude that both B-cell quantity and particularly a B-cell-related gene, GPR18, can serve as clinically useful biomarkers for prognosis in multiple cancers. Furthermore, we have been first to uncover that GPR18-expressing B-cells may be specifically linked to cytotoxic T-cell functions, that is the capacity to kill cancer cells directly. Currently, not much is known about GPR18 in human cancer. Future functional studies of this gene can help us understand how B-cell cooperates with T-cell immunity in human cancer, and affects cancer patient survival in so many cancer types.”
The research study was led by Professor LUI and first-authored by the post-doctoral fellow Dr. Yuchen LIU. The study was funded by the Lee Hysan Foundation Research Grant and Endowment Fund Research Grant Schemes, United College, CUHK (CA11281; CA11286). Study details can refer to: https://www.nature.com/articles/s42003-020-0964-7.
Associate Professor Professor Vivian Wai Yan LUI, (center), post-doctoral fellows Dr. Yuchen LIU (left) and Dr. Wang LI from the School of Biomedical Sciences at CU Medicine together wrote the study.
